Article Abstract

Aspirin monotherapy vs. dual antiplatelet therapy in diabetic patients following coronary artery bypass graft (CABG): where do we stand?

Authors: Salem Salem, Sameh Askandar, Rami N. Khouzam


Coronary heart disease (CHD) is the most common cause of death in the United States and worldwide (1). Rupture of atherosclerotic plaque, followed by platelet aggregation and thrombus formation often leads to partial or complete occlusion of the native coronary artery, resulting in myocardial ischemia. Regardless of the revascularization modality used vs. medical therapy alone for patients with stable ischemic heart disease or acute coronary syndrome (ACS), antiplatelet therapy remains the standard of care.